Clinical Trial

Umbilical Cord Mesenchymal Stem Cells (UC-MSC) in the Treatment of Systemic Sclerosis

Study acronym: HS_SW01
Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to evaluate the safety and tolerability of human umbilical cord mesenchymal stem cell injection(HS\_SW01 Cells injection) in patients with systemic sclerosis, and to further explore its pharmacokinetics(PK), immunological profile and preliminary efficacy. Participants will be required to sign the informed consent form and will only be assigned to the study and enrolled after undergoing a series of tests and meeting the inclusion and exclusion criteria of the protocol.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-04-15.
Trial Details
NCT Number NCT07535931
Lead Sponsor Shenzhen Huishan Biotechnology Co., Ltd.
Collaborators: Southern Medical University, China
Conditions Systemic Sclerosis (SSc)
Enrollment 21 participants
Start Date 2026-04-10
Primary Completion 2027-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-21